Strides Pharma gains 3 per cent on FDA approval for Prednisone Tablets
February 12, 2021
The product will be manufactured at Bengaluru facility
The shares of Strides Pharma Science Limited (Strides) gained 3 per cent during the afternoon trade on Friday after the company announced that it had received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA).
At 1:13 pm, Strides Pharma was trading at ₹895.40 on the BSE, up ₹29.60 or 3.42 per cent.
It hit an intraday high of ₹902.25 and an intraday low of ₹868.45. It opened at ₹873.25 as against the previous close of ₹865.80.
On the NSE, it was trading at ₹895.00, up ₹28.75 or 3.32 per cent. It hit an intraday high of ₹902.00 and an intraday low of ₹866.30.
Read more about Strides Pharma rises after USFDA nod for Prednisone tablets on Business Standard. Strides Pharma rose 2.96% to Rs 891.4 after the drug company announced that its step-down wholly owned subsidiary has received US drug regulator s approval for Prednisone tablets.
The approved product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Deltasone tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co.
New Delhi, Feb 12: Drug firm Strides Pharma Science on Friday said its subsidiary, Strides Pharma Global Pte Ltd, has received approval from the US health